Summary
Two recently approved Alzheimer's medications, Leqembi and Kisunla, are seeing much lower use among Medicare patients than the government originally expected. Just a couple of years ago, federal officials projected that Medicare would spend billions of dollars every year on these treatments. Now, the Centers for Medicare and Medicaid Services is not forecasting any significant spending on these drugs for 2026 or 2027.
The dramatic shift comes down to a mix of heavy logistical hurdles and complex medical realities. Getting these treatments is not as simple as picking up a daily pill at the pharmacy. The drugs must be administered intravenously, meaning they are infused directly into a patient's veins. This requires regular hospital or clinic visits, and patients must also undergo frequent brain imaging scans to safely monitor their progress.
Beyond the challenging logistics, the treatments are restricted to a narrow group of eligible patients. Doctors and families are also carefully weighing the actual medical value of the medications. Experts note that the drugs currently offer minimal meaningful clinical benefits while carrying a risk of severe side effects, such as brain bleeding. Together, these limitations have heavily hindered the widespread rollout of the medications.
Why it matters.
This steep drop in expected use provides a major reality check for both the pharmaceutical industry and the broader healthcare system. When highly anticipated treatments first secure government approval, initial financial projections can easily overestimate real-world demand. The massive shift from billions of dollars in projected annual spending down to insignificant forecasts for 2026 and 2027 shows that severe safety concerns and logistical barriers can quickly cool the market, regardless of early excitement.
For patients and their families, this trend underscores the deeply personal and difficult choices involved in managing Alzheimer's disease. Families are realizing they must weigh whether a drug's minimal clinical benefits are worth an intense schedule of hospital visits and the serious risk of brain bleeding. Moving forward, this serves as a clear signal to drug developers that the next generation of Alzheimer's treatments needs to be safer, easier to administer, and noticeably more effective to truly reach a wide population.
The story in numbers.
- Years for which CMS forecasts no significant spending
- 2026-2027
- Years since initial projections of billions in annual spending
- 2
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.